Ze Hua Zhao
Director of Finance/CFO chez UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED
Profil
Ze Hua Zhao is an Executive Director & General Manager-Finance at Universal Health International Group Holding Ltd.
He previously worked as a Finance Manager & Deputy General Manager at Chengde Tianyuan Pharmaceutical Industry Co., Ltd.
Mr. Zhao completed his undergraduate degree from Hebei Radio & TV University in 1992.
Postes actifs de Ze Hua Zhao
| Sociétés | Poste | Début |
|---|---|---|
| UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED | Director of Finance/CFO | 01/10/2011 |
Anciens postes connus de Ze Hua Zhao
| Sociétés | Poste | Fin |
|---|---|---|
Chengde Tianyuan Pharmaceutical Industry Co., Ltd.
 Chengde Tianyuan Pharmaceutical Industry Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Goldenmax International Group Ltd., Chengde Tianyuan Pharmaceutical Industry Co., Ltd. is a pharmaceutical company that manufactures pharmaceutical preparations. The private company is based in Chengde, China. Chengde Tianyuan Pharmaceutical Industry Co. was acquired by Goldenmax International Group Ltd. on October 23, 2019 for $26.17 million. | Director of Finance/CFO | 01/12/2004 |
Formation de Ze Hua Zhao
| Hebei Radio & TV University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED | Retail Trade |
| Entreprise privées | 1 |
|---|---|
Chengde Tianyuan Pharmaceutical Industry Co., Ltd.
Chengde Tianyuan Pharmaceutical Industry Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Goldenmax International Group Ltd., Chengde Tianyuan Pharmaceutical Industry Co., Ltd. is a pharmaceutical company that manufactures pharmaceutical preparations. The private company is based in Chengde, China. Chengde Tianyuan Pharmaceutical Industry Co. was acquired by Goldenmax International Group Ltd. on October 23, 2019 for $26.17 million. | Health Technology |
